

# Shingrix



## 1. NAME OF THE MEDICINAL PRODUCT

### Shingrix

Herpes zoster (HZ, or shingles) vaccine (non-live recombinant, AS01<sub>B</sub> adjuvanted)

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

After reconstitution, 1 dose (0.5 ml) contains 50 micrograms of gE antigen<sup>1</sup> adjuvanted with AS01<sub>B</sub><sup>2</sup>.

<sup>1</sup> Varicella Zoster Virus (VZV) glycoprotein E (gE) produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells

<sup>2</sup> The GlaxoSmithKline proprietary AS01<sub>B</sub> Adjuvant System is composed of the plant extract *Quillaja saponaria* Molina, fraction 21 (QS-21) (50 micrograms) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from *Salmonella minnesota* (50 micrograms)

The powder is white.

The suspension is an opalescent, colourless to pale brownish liquid.

For excipients, see section 6.1 *List of Excipients*.

## 3. PHARMACEUTICAL FORM

Powder and suspension for suspension for injection.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic Indications

Shingrix is indicated for the prevention of herpes zoster (HZ) and HZ-related complications, such as post-herpetic neuralgia (PHN), in:

- adults 50 years of age or older;
- adults 18 years of age or older at increased risk of HZ.

The use of Shingrix should be based on official recommendations.

### 4.2 Posology and Method of Administration

The immunisation schedules for Shingrix should be based on official recommendations.

#### Posology

The primary vaccination schedule consists of two doses of 0.5 ml each; an initial dose followed by a second dose 2 to 6 months later.

For subjects who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, and whom would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose (see section 5.1 *Pharmacodynamic Properties*).

The need for booster doses has not been established.

Shingrix can be given with the same schedule in individuals previously vaccinated with live attenuated HZ vaccine (see section 5.1 *Pharmacodynamic Properties*).

Shingrix is not indicated for prevention of primary varicella infection.

#### **Method of administration**

Shingrix is for intramuscular injection only, preferably in the deltoid muscle.

For instructions on reconstitution of the medicinal product before administration, see section 6.6 *Instructions for Use and Handling*.

#### **4.3 Contraindications**

Hypersensitivity to the active substances or to any component of the vaccine (see section 2. *Qualitative and Quantitative Composition* and 6.1 *List of Excipients*).

#### **4.4 Special Warnings and Precautions for Use**

##### **Prior to immunisation**

It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. As with other vaccines, vaccination with Shingrix should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

As with any vaccine, a protective immune response may not be elicited in all vaccines.

In a post-marketing observational study in individuals aged 65 years or older, an increased risk of Guillain-Barré syndrome (estimated 3 excess cases per million doses administered) was observed during the 42 days following vaccination with Shingrix. Available information is insufficient to determine a causal relationship with Shingrix.

##### **Precautions for use**

##### **Do not administer the vaccine intravascularly, intradermally or subcutaneously.**

Maladministration via the subcutaneous route may lead to an increase in transient local reactions.

As with other vaccines administered intramuscularly, Shingrix should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

#### **4.5 Interaction with Other Medicinal Products and Other Forms of Interactions**

##### **Use with other vaccines**

Shingrix can be given concomitantly with unadjuvanted seasonal influenza vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23), pneumococcal conjugate vaccine (PCV), reduced antigen diphtheria-tetanus-acellular pertussis vaccine (dTpa) or coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine (see section 5.1 *Pharmacodynamic Properties*).

The adverse reactions of fever and shivering were more frequent when PPV23 vaccine was co-administered with Shingrix compared to when Shingrix was given alone (see section 4.8 *Undesirable Effects*).

If Shingrix is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.

#### 4.6 Use During Pregnancy and Lactation

##### Fertility

Animal studies indicate no effects of Shingrix on male or female fertility.

##### Pregnancy

There are no data on the use of Shingrix in pregnant women. Animal studies performed with Shingrix administered to female rats do not indicate any harmful effects with respect to pregnancy (see *Non-clinical information*).

##### Lactation

The effect on breast-fed infants of administration of Shingrix to their mothers has not been studied.

#### 4.7 Effects on Ability to Drive and Use Machines

No studies on the effects of Shingrix on the ability to drive and use machines have been performed.

#### 4.8 Undesirable Effects

##### Clinical trial data

The safety profile presented below is based on a pooled analysis of more than 14,500 adults  $\geq$  50 years of age, who have received at least one dose of Shingrix. These data were generated in placebo-controlled clinical studies (conducted in Europe, North America, Latin America, Asia and Australia) where Shingrix was administered according to a 0, 2-month schedule.

Additionally, in clinical studies, 1,587 subjects  $\geq$  18 years of age who are immunodeficient or immunosuppressed due to disease or therapy (referred to as immunocompromised (IC)), were vaccinated with at least 1 dose of Shingrix. The reported adverse reactions were consistent with those presented in the Table below.

Adverse reactions reported are listed according to the following frequency:

Very common	$\geq 1/10$
Common	$\geq 1/100$ to $< 1/10$
Uncommon	$\geq 1/1,000$ to $< 1/100$
Rare	$\geq 1/10,000$ to $< 1/1,000$
Very rare	$< 1/10,000$

System Organ Class	Frequency	Adverse reactions
Nervous system disorders	Very common	headache
Gastrointestinal disorders	Very common	gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain)
Musculoskeletal and connective tissue disorders	Very common	myalgia
	Uncommon	arthralgia

General disorders and administration site conditions	Very common	injection site reactions (such as pain, redness, swelling), fatigue, chills, fever
	Common	injection site pruritus, malaise

Overall, there was a higher incidence of some adverse reactions in younger age groups. However, the overall frequency and severity of these events did not indicate a clinically meaningful different reactogenicity profile in the younger age strata. In IC adult studies, there was a higher incidence of pain at the injection site, fatigue, myalgia, headache, shivering and fever in subjects aged 18 to 49 years compared with those aged 50 years and older. In older adult studies, there was a higher incidence of pain and swelling at the injection site, fatigue, myalgia, headache, shivering, fever and gastrointestinal symptoms in subjects aged 50 to 69 years compared with those aged 70 years and older.

In a clinical study where 119 subjects  $\geq 50$  years of age were vaccinated with Shingrix following a 0, 6-month schedule, the safety profile was similar to that observed in subjects vaccinated with Shingrix following a 0, 2-month schedule.

In a clinical study including 865 adults  $\geq 50$  years of age, fever and shivering were reported more frequently when PPV23 vaccine was co-administered with Shingrix (16% and 21%, respectively) compared to when Shingrix was given alone (7% for both adverse reactions).

### Post-marketing data

System Organ Class	Frequency	Adverse reactions
Immune system disorders	Rare	hypersensitivity reactions including rash, urticaria, angioedema

### 4.9 Overdose

Insufficient data are available.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Varicella zoster vaccines, ATC code: J07BK03.

#### Mechanism of Action

Shingrix is designed to induce antigen-specific cellular and humoral immune responses in individuals with pre-existing immunity against VZV.

Non-clinical data show that AS01<sub>B</sub> induces a local and transient activation of the innate immune system through specific molecular pathways. This facilitates the recruitment and activation of antigen presenting cells carrying gE-derived antigens in the draining lymph node, which in turn leads to the generation of gE-specific CD4<sup>+</sup> T cells and antibodies. The adjuvant effect of AS01<sub>B</sub> is the result of interactions between MPL and QS-21 formulated in liposomes.

#### Pharmacodynamic Effects

##### 1. Efficacy of Shingrix

##### Efficacy against Herpes Zoster (HZ) and Post-Herpetic Neuralgia (PHN)

Two phase III, placebo-controlled, observer-blind efficacy studies of Shingrix were conducted in adults  $\geq 50$  years with 2 doses administered 2 months apart:

- Zoster-006 (ZOE-50): total vaccinated cohort (TVC) of 15,405 subjects  $\geq 50$  years who received at least one dose of either Shingrix (N=7,695) or placebo (N=7,710).

- Zoster-022 (ZOE-70): TVC of 13,900 subjects  $\geq 70$  years who received at least one dose of either Shingrix (N=6,950) or placebo (N=6,950).

Two phase III, placebo-controlled, observer-blind studies evaluating Shingrix efficacy were conducted in IC adults  $\geq 18$  years with 2 doses administered 1-2 months apart:

- Zoster-002: TVC of 1,846 autologous hematopoietic stem cell transplants (aHSCT) recipients who received at least one dose of either Shingrix (N=922) or placebo (N=924) post-transplant.

- Zoster-039: TVC of 562 subjects with hematologic malignancies who received at least one dose of either Shingrix (N=283) or placebo (N=279) during a cancer therapy course or after the full cancer therapy course.

Incidence of HZ and PHN cases as well as vaccine efficacy were evaluated in the modified Total Vaccinated Cohort (mTVC i.e. excluding subjects who did not receive the second dose of vaccine or who had a confirmed diagnosis of HZ within one month after the second dose).

Shingrix significantly decreased the incidence of HZ and PHN compared with placebo in:

- adults  $\geq 50$  years (Zoster-006): 6 vs. 210 HZ cases and 0 vs. 18 PHN cases;

- adults  $\geq 70$  years (pooled analysis of Zoster-006 and Zoster-022): 25 vs. 284 HZ cases and 4 vs. 36 PHN cases;

- adults  $\geq 18$  years with aHSCT (Zoster-002): 49 vs. 135 HZ cases and 1 vs. 9 PHN cases;

- adults  $\geq 18$  years with hematologic malignancies (Zoster-039): 2 vs. 14 HZ cases (PHN was not assessed as study endpoint). Vaccine efficacy was calculated post-hoc.

Vaccine efficacy results are presented in Table 1.

**Table 1:** Shingrix efficacy against HZ and PHN (mTVC)

Age (years)	HZ			PHN		
	N	Efficacy (%)	95% CI	N	Efficacy (%)	95% CI
<b>Zoster-006*</b>						
$\geq 50$	7,344	97.2	93.7; 99.0	7,340	100.0	77.1; 100.0
<b>50-59</b>	3,492	96.6	89.6; 99.4	3,491	100.0	40.8; 100.0
$\geq 60$	3,852	97.6	92.7; 99.6	3,849	100.0	55.2; 100.0
<b>60-69</b>	2,141	97.4	90.1; 99.7	2,140	100.0 <sup>§</sup>	< 0; 100.0
<b>Pooled Zoster-006 and Zoster-022**</b>						
$\geq 70$	8,250	91.3	86.8; 94.5	8,250	88.8	68.7; 97.1
<b>70-79</b>	6,468	91.3	86.0; 94.9	6,468	93.0	72.4; 99.2
$\geq 80$	1,782	91.4	80.2; 97.0	1,782	71.2 <sup>§</sup>	< 0; 97.1
<b>Zoster-002*** (aHSCT recipients<sup>#</sup>)</b>						
$\geq 18$	870	68.2	55.5; 77.6	870	89.3	22.5; 99.8

<b>18-49</b>	213	71.8	38.7; 88.3	213	100.0 <sup>§</sup>	< 0; 100.0
<b>≥ 50</b>	657	67.3	52.6; 77.9	657	88.0	10.4; 99.8
<b>Zoster-039 (hematologic malignancy patients<sup>#</sup>)</b>						
<b>≥ 18</b>	259	87.2 <sup>****</sup>	44.2; 98.6	-	-	-

N Number of evaluable subjects

CI Confidence interval

\* Over a median follow-up period of 3.1 and 4.1 years for reporting HZ and PHN cases, respectively

\*\* Over a median follow-up period of 4.0 years for reporting HZ and PHN cases

\*\*\* Over a median follow-up period of 21 months for reporting HZ and PHN cases

\*\*\*\* VE calculation was performed post-hoc; median follow-up period of 11.1 months

<sup>#</sup> antiviral prophylaxis in line with the local standard of care was permitted

<sup>§</sup> Not statistically significant

Zoster-006 mTVC: N (Shingrix) = 7,344, N (Placebo) = 7,415

Pooled analysis of Zoster-006 and Zoster-022 mTVC: N (Shingrix) = 8,250, N (Placebo) = 8,346

Zoster-002 mTVC: N (Shingrix) = 870, N (Placebo) = 851

Zoster-039 mTVC: N (Shingrix) = 259, N (Placebo) = 256

In the fourth year after vaccination, the efficacy against HZ was 93.1 % (95% CI: 81.2; 98.2) and 87.9% (95% CI: 73.3; 95.4) in subjects ≥ 50 years (Zoster-006) and subjects ≥ 70 years (pooled Zoster-006 and Zoster-022), respectively.

In Zoster-002, during a follow-up period starting 1 month post-dose 2 (i.e. corresponding to approximately 6 months after aHSCT) until 1 year after aHSCT, when the risk for HZ is the highest, the efficacy against HZ was 76.2% (95% CI: 61.1; 86.0).

#### Efficacy against other HZ-related complications

The evaluated HZ-related complications (other than PHN) were: HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease including stroke, and visceral disease.

In the pooled analysis of Zoster-006 and Zoster-022, Shingrix significantly reduced HZ-related complications by 93.7% (95% CI: 59.5; 99.9) and 91.6% (95% CI: 43.3; 99.8) in subjects ≥ 50 years (1 vs. 16 cases) and subjects ≥ 70 years (1 vs. 12 cases), respectively.

In Zoster-002, Shingrix significantly reduced HZ-related complications by 77.8% (95% CI: 19.0; 96.0) in aHSCT recipients ≥ 18 years (3 vs 13 cases).

In addition, in Zoster-002, Shingrix significantly reduced HZ-related hospitalisations by 84.7% (95% CI: 32.1; 96.6) (2 vs. 13 cases).

#### Effect of Shingrix on HZ-associated pain

In Zoster-022, Shingrix significantly reduced the use and the duration of HZ-associated pain medication by 39.6% (95% CI: 10.7; 64.8) and 49.3% (95% CI: 2.9; 73.5), respectively, in subjects ≥ 70 years with at least one confirmed HZ episode. The median duration of pain medication use was 30.0 and 38.0 days in the Shingrix and placebo group, respectively.

Overall there was a general trend towards less severe HZ-associated pain in subjects vaccinated with Shingrix compared to placebo.

In Zoster-002, Shingrix significantly reduced the duration of severe ‘worst’ HZ-associated pain by 38.5% (95% CI: 11.0; 57.6) in aHSCT recipients ≥ 18 years with at least one confirmed HZ episode.

## **2. Immunogenicity of Shingrix**

An immunological correlate of protection has not been established; therefore the level of immune response that provides protection against HZ is unknown.

In adults  $\geq 50$  years, the immune responses to Shingrix were evaluated in a subset of subjects from the phase III efficacy studies Zoster-006 [humoral immunity and cell-mediated immunity (CMI)] and Zoster-022 (humoral immunity). The gE-specific immune responses (humoral and CMI) elicited by Shingrix at 1 month post-dose 2 are presented in Tables 2 and 3, respectively.

**Table 2:** Humoral immunogenicity of Shingrix in adults  $\geq 50$  years at 1 month post-dose 2 (ATP cohort for immunogenicity)

<b>Anti-gE immune response<sup>^</sup></b>				
<b>Age group (years)</b>	<b>N</b>	<b>VRR<sup>§</sup> (%) (95% CI)</b>	<b>GMC (95% CI)</b>	<b>Median fold increase of concentrations vs pre-vaccination (Q1; Q3)</b>
<b>Zoster-006</b>				
<b><math>\geq 50</math></b>	1,070	98.5 (97.6; 99.1)	52,376.6 (50,264.1; 54,577.9)	41.9 (20.8; 86.9)
<b>Pooled Zoster-006 and Zoster-022</b>				
<b><math>\geq 70</math></b>	742	96.6 (95.1; 97.8)	49,691.5 (47,250.8; 52,258.2)	34.3 (16.7; 68.5)

ATP According-To-Protocol

<sup>^</sup> Anti-gE immune response = anti-gE antibody levels, measured by anti-gE enzyme-linked immunosorbent assay (gE ELISA)

N Number of evaluable subjects at the specified time point (for the GMC)

<sup>§</sup> Vaccine response rate (VRR) for anti-gE is defined as the percentage of subjects who have at least a 4-fold increase in the post-dose 2 anti-gE antibodies concentration as compared to the pre-vaccination anti-gE antibodies (subjects seropositive at baseline), or as compared to the anti-gE antibodies cut-off value for seropositivity (subjects seronegative at baseline)

CI Confidence interval

GMC Geometric Mean Concentration

Q1; Q3 First and third quartiles

At 3 years post-dose 2, the median fold increase over baseline was 9.3 (Q1: 4.9; Q3: 19.5) in adults  $\geq 50$  years (Zoster-006) and 7.2 (Q1: 3.5; Q3: 14.5) in adults  $\geq 70$  years (pooled Zoster-006 and Zoster-022).

**Table 3:** Cell-mediated immunogenicity of Shingrix in adults  $\geq 50$  years at 1 month post-dose 2 (ATP cohort for immunogenicity)

gE-specific CD4[2+] T cell response <sup>^</sup>			
Age group (years)	N	Median frequency (Q1; Q3)	Median fold increase of frequency vs. pre-vaccination (Q1; Q3)
<b>Zoster-006</b>			
$\geq 50$	164	1,844.1 (1,253.6; 2,932.3)	24.6 (9.9; 744.2)
$\geq 70^*$	52	1,494.6 (922.9; 2,067.1)	33.2 (10.0; 1,052.0)

ATP According-To-Protocol

<sup>^</sup> gE-specific CD4[2+] T cell response = gE-specific CD4+ T cell activity, measured by intracellular cytokine staining (ICS) assay (CD4[2+] T cells = CD4+ T cells expressing at least 2 of 4 selected immune markers)

N Number of evaluable subjects at the specified time point for the median frequency

Q1; Q3 First and third quartiles

\* The gE-specific CD4[2+] data in the  $\geq 70$  YOA group were only generated in Zoster-006 because CD4+ T cell activity was not assessed in Zoster-022

At 3 years post-dose 2, in Zoster-006, the median fold increase over baseline was 7.9 (Q1: 2.7; Q3: 31.6) in adults  $\geq 50$  years and 7.3 (Q1: 1.7; Q3: 31.6) in adults  $\geq 70$  years.

Data from a phase II, open-label, single group, follow-up clinical study in adults  $\geq 60$  years (Zoster-024) indicate that the vaccine-induced immune response (humoral and CMI) persists up to Month 72 (approximately 6 years post-dose 1 i.e. 70 months post-dose 2), following a 0, 2-month schedule (N= 119).

The median anti-gE antibody concentration was greater than 7-fold above the baseline pre-vaccination median concentration. The median frequency of gE-specific CD4[2+] T cells was greater than 3.7-fold above baseline pre-vaccination median frequency.

In IC adults  $\geq 18$  years, the humoral and CMI responses to Shingrix were evaluated in:

- one phase I/II study: Zoster-015 (HIV infected subjects);
- one phase II/III study: Zoster-028 (patients with solid tumors undergoing chemotherapy);
- three phase III studies: Zoster-002 (aHSCT recipients vaccinated post-transplant), Zoster-039 (patients with hematologic malignancies vaccinated during a cancer therapy course or after the full cancer therapy course) and Zoster-041 (renal transplant recipients on chronic immunosuppressive treatment at the time of vaccination).

The gE-specific immune responses (humoral and CMI) elicited by Shingrix at 1 month post-dose 2 in all IC populations studied are presented in Tables 4 and 5, respectively.



**Table 4:** Humoral immunogenicity of Shingrix in IC adults  $\geq 18$  years at 1 month post-dose 2 (ATP cohort for immunogenicity)

<b>Anti-gE immune response<sup>^</sup></b>			
<b>N</b>	<b>VRR<sup>§</sup> (%) (95% CI)</b>	<b>GMC (95% CI)</b>	<b>Median fold increase of concentrations vs pre- vaccination (Q1; Q3)</b>
<b>Zoster-002 (aHSCT recipients)</b>			
82	67.1 (55.8; 77.1)	12,753.2 (7,973.0; 20,399.4)	14.1 (1.7; 137.0)
<b>Zoster-028 (solid tumor patients)</b>			
87	86.2 (77.1; 92.7)	18,291.7 (14,432.1; 23,183.5)	21.5 (7.0; 45.2)
<b>Zoster-039 (hematologic malignancy patients)</b>			
217	65.4 (58.7; 71.7)	13,445.6 (10,158.9; 17,795.6)	17.2 (1.4; 87.4)
<b>Zoster-041 (renal transplant recipients)</b>			
121	80.2 (71.9; 86.9)	19,163.8 (15,041.5; 24,416.0)	15.1 (6.1; 35.0)
<b>Zoster-015 (HIV infected subjects)</b>			
53	98.1 (89.9; 100)	42,723.6 (31,233.0; 58,441.6)	40.9 (18.8; 93.0)

ATP According-To-Protocol

<sup>^</sup> Anti-gE immune response = anti-gE antibody levels, measured by anti-gE enzyme-linked immunosorbent assay (gE ELISA)

N Number of evaluable subjects at the specified time point (for the GMC)

<sup>§</sup> Vaccine response rate (VRR) for anti-gE is defined as the percentage of subjects who have at least a 4-fold increase in the post-dose 2 anti-gE antibodies concentration as compared to the pre-vaccination anti-gE antibodies (subjects seropositive at baseline), or as compared to the anti-gE antibodies cut-off value for seropositivity (subjects seronegative at baseline)

CI Confidence interval

GMC Geometric Mean Concentration

Q1; Q3 First and third quartiles

**Table 5:** Cell-mediated immunogenicity of Shingrix in IC adults  $\geq 18$  years at 1 month post-dose 2 (ATP cohort for immunogenicity)

<b>gE-specific CD4[2+] T cell response<sup>^</sup></b>		
<b>N</b>	<b>Median frequency (Q1; Q3)</b>	<b>Median fold increase of frequency vs. pre-vaccination (Q1; Q3)</b>
<b>Zoster-002 (aHSCT recipients)</b>		
51	6,644.9 (1,438.3; 13,298.6)	109.0 (34.4; 2,716.4)
<b>Zoster-028* (solid tumor patients)</b>		
22	778.8 (393.1; 1,098.2)	4.9 (1.7; 33.0)
<b>Zoster-039 (hematologic malignancy patients)</b>		
53	3,081.9 (1,766.2; 7,413.6)	45.9 (16.4; 2,221.9)
<b>Zoster-041 (renal transplant recipients)</b>		
32	2,149.0 (569.4; 3,695.1)	47.7 (14.7; 439.6)
<b>Zoster-015 (HIV infected subjects)</b>		
41	2,809.7 (1,554.5; 4,663.7)	23.4 (8.5; 604.1)

ATP According-To-Protocol

<sup>^</sup> gE-specific CD4[2+] T cell response = gE-specific CD4+ T cell activity, measured by intracellular cytokine staining (ICS) assay (CD4[2+] T cells = CD4+ T cells expressing at least 2 of 4 selected immune markers)

N Number of evaluable subjects at the specified time point for the median frequency

Q1; Q3 First and third quartiles

\* Blood for CMI was only collected from the group of subjects that received the first dose of Shingrix 8-30 days before the start of a chemotherapy cycle (i.e. largest group of the study)

At 1 year post-dose 2, the median fold increase over baseline ranged from 2.7 to 6.5 in terms of anti-gE antibody concentration and from 2.0 to 43.6 in terms of gE-specific CD4[2+] T-cell frequencies (studies Zoster-002, Zoster-028, Zoster-039 and Zoster-041).

At 2 years post-dose 2, in Zoster-002, the median fold increase over baseline was 1.3 in terms of anti-gE antibody concentration and 50.9 in terms of gE-specific CD4[2+] T-cell frequencies.

#### Immunogenicity following concomitant vaccination

In five phase III, controlled, open-label clinical studies, adults  $\geq 50$  years of age were randomized to receive 2 doses of Shingrix 2 months apart administered either concomitantly at the first dose or non-concomitantly with unadjuvanted seasonal influenza vaccine (N=828; Zoster-004), PPV23 vaccine (N=865; Zoster-035), PCV13 vaccine (N=912; Zoster-059), dTpa vaccine formulated with 0.3 milligrams Al<sup>3+</sup> (N=830; Zoster-042) or monovalent COVID-19 mRNA-1273 50 micrograms booster vaccine (Original SARS-CoV-2 strain) (N=539; Zoster-091). The vaccine response rate (in terms of anti-gE antibodies) was 95.8% (95% CI: 93.3; 97.6), 98.3% (95% CI: 96.4; 99.3), 99.1% (95% CI: 97.6; 99.7) and 97.8% (95% CI: 95.8; 99.1) and 97.4% (95% CI: 94.4; 99.0) following co-administration of Shingrix with the influenza, PPV23, PCV13, dTpa and COVID-19 mRNA-1273 booster vaccine respectively. The immune

responses of the co-administered vaccines were unaffected, with the exception of lower geometric mean concentrations (GMCs) for one of the pertussis antigens (pertactin) when Shingrix is coadministered with the dTpa vaccine. However, these data do not suggest clinically relevant interference.

#### Immunogenicity in subjects with a history of HZ prior to vaccination

In a phase III, uncontrolled, open-label clinical study (Zoster-033), 96 adults  $\geq 50$  years of age, with a history of HZ, received 2 doses of Shingrix 2 months apart. The vaccine response rate (anti-gE antibodies) at 1 month post-vaccination was 90.2% (95% CI: 81.7; 95.7).

#### Immunogenicity in subjects receiving 2 doses of Shingrix 6 months apart

In a phase III, open-label clinical study (Zoster-026) where 238 subjects  $\geq 50$  years of age were equally randomised to receive 2 doses of Shingrix 2 or 6 months apart, the vaccine response rate (anti-gE antibodies) at 1 month post-vaccination following the 0, 6-month schedule was 96.5% (95% CI: 90.4; 99.2).

The humoral immune response (anti-gE antibodies concentration) following the 0, 6-month schedule was not inferior to the humoral immune response following the 0, 2-month schedule, as the 97.5% CI upper limit of the antibodies concentration ratio was below 1.50 [1.16 (97.5% CI: 0.98; 1.39)].

#### Immunogenicity in individuals previously vaccinated with live attenuated herpes zoster (HZ) vaccine

In a phase III, open-label, multicentre clinical study (Zoster-048), 430 adults  $\geq 65$  years of age with or without a previous history of vaccination with live attenuated HZ vaccine  $\geq 5$  years earlier were group-matched at a 1:1 ratio to receive 2 doses of Shingrix 2 months apart. The immune response to Shingrix was unaffected by prior vaccination with live attenuated HZ vaccine.

#### **Pharmacokinetics**

Evaluation of pharmacokinetic properties is not required for vaccines.

#### **Clinical Studies**

See section 5.1 *Pharmacodynamic Properties*.

### **5.3 Preclinical Safety Data**

#### **Reproductive Toxicology**

Administration of VZV gE AS01<sub>B</sub> to female rats did not indicate any harmful effects with respect to fertility, pregnancy, embryo-foetal development, parturition or postnatal development.

Treatment of male rats did not affect mating performance, fertility or early embryonic development.

#### **Animal toxicology and/or pharmacology**

Non-clinical data reveal no special hazard for humans based on conventional studies of acute and repeated dose toxicity, local tolerance and cardiovascular/respiratory safety pharmacology.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of Excipients**

#### **Powder (gE antigen):**

Sucrose

Polysorbate 80

Sodium dihydrogen phosphate dihydrate  
Dipotassium phosphate

**Suspension (AS01<sub>B</sub> Adjuvant System):**

Diioleoyl phosphatidylcholine  
Cholesterol  
Sodium chloride  
Disodium phosphate anhydrous  
Potassium dihydrogen phosphate  
Water for injections

**6.2 Incompatibilities**

This medicinal product must not be mixed with other medicinal products.

**6.3 Shelf Life**

The expiry date of the vaccine is indicated on the label and packaging.

For shelf-life after reconstitution of the medicinal product, see section 6.6 *Instructions for Use and Handling*.

**6.4 Special Precautions for Storage**

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Store in the original package in order to protect from light.

For storage conditions after reconstitution of the medicinal product, see section 6.6 *Instructions for Use and Handling*.

**6.5 Nature and Contents of Container**

- Powder for 1 dose in a vial (type I glass) with a stopper (butyl rubber)
- Suspension for 1 dose in a vial (type I glass) with a stopper (butyl rubber).

Shingrix is available in a pack size of 1 vial of powder plus 1 vial of suspension or in a pack size of 10 vials of powder plus 10 vials of suspension.

**6.6 Instructions for Use and Handling**

The powder and suspension should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not reconstitute the vaccine.

**How to prepare Shingrix:**

Shingrix must be reconstituted prior to administration.

1. Withdraw the entire contents of the vial containing the suspension into the syringe.
2. Add the entire contents of the syringe into the vial containing the powder.
3. Shake gently until the powder is completely dissolved.

The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not administer the vaccine.

After reconstitution, the vaccine should be used promptly; if this is not possible, the vaccine should be stored in a refrigerator (2°C – 8°C). If not used within 6 hours it should be discarded.

**Before administration:**

1. Withdraw the entire contents of the vial containing the reconstituted vaccine into the syringe.
  2. Change the needle so that you are using a new needle to administer the vaccine.
- Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORIZATION HOLDER**

GlaxoSmithKline (Thailand) Ltd.

**8. MARKETING AUTHORIZATION NUMBER**

1C 9/66 (NBC)

**9. DATE OF AUTHORIZATION**

27-Jun-2023

**10. DATE OF REVISION OF THE TEXT**

24-Feb-2023

Trade marks owned or licensed by GSK.

© 2023 GSK group of companies or its licensor

SHINGRIX IM GDS08/IPI03 TH